Abstract:
:Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce the development of ADAbs. This review article aims to assess the immunogenicity of biologic therapies and their clinical implications. A comprehensive literature search was conducted for articles published January 2009 to August 2015 reporting immunogenicity to adalimumab (ADM), certolizumab pegol (CZP), golimumab, infliximab (IFX), ustekinumab, and vedolizumab in inflammatory bowel disease (IBD). Eligible articles were reviewed and quality assessed by independent reviewers. Overall, 122 publications reporting 114 studies were assessed. ADAbs were reported for all agents, but the percentage of patients developing ADAbs was extremely variable, with the highest (65.3%) being for IFX administration to patients with IBD. ADAb presence was frequently associated with a reduction in primary efficacy and a loss of response, and, for IFX, an increase in adverse events (AEs). Lower serum levels of ADM, CZP and IFX were seen in ADAbs-positive rather than ADAbs-negative patients; pharmacokinetic data were unavailable for other therapies. Little information was available regarding the timing of ADAb development; studies reported their detection from as early as 10-14 days up to months after treatment initiation. Biologic therapies carry an intrinsic risk of immunogenicity, although reported rates of ADAbs vary considerably. The clinical implications of immunogenicity are a concern for effective treatment; further research, particularly into the more recently approved biologics, is required.
journal_name
Therap Adv Gastroenteroljournal_title
Therapeutic advances in gastroenterologyauthors
Vermeire S,Gils A,Accossato P,Lula S,Marren Adoi
10.1177/1756283X17750355subject
Has Abstractpub_date
2018-01-21 00:00:00pages
1756283X17750355eissn
1756-283Xissn
1756-2848pii
10.1177_1756283X17750355journal_volume
11pub_type
杂志文章abstract:Background:Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and hospital cost savings related to FMT are unknown. The aim of this study was to calculate the cost of an FMT and the total hospital costs...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819843002
更新日期:2019-04-10 00:00:00
abstract::Erratum to 'Possible interactions between dietary fibres and 5-aminosalicyclic acid' by C Henriksen, S Hansen, I Nordgaard-Lassen, J Rikardt Anderson and P Madsen. Therapeutic Advances in Gastroenterology (2010) 3(1) 5-9 [DOI: 10.1177/ 1756283X09347810][This corrects the article on p. 5 in vol. 3.]. ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 已发布勘误
doi:10.1177/1756283X10363751
更新日期:2012-09-01 00:00:00
abstract:BACKGROUND:Dual red imaging (DRI), a novel image-enhanced endoscopic technique, is expected to improve visibility of thin vessels, but no reports of the clinical use of DRI in colorectal endoscopic submucosal dissection (ESD) have been published. We aimed to compare the visibility of vessels, demarcation line between t...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16645501
更新日期:2016-09-01 00:00:00
abstract:BACKGROUND:Self-expandable metal stent (SEMS) placement is a minimally invasive treatment for palliation of malignant colorectal strictures and as a bridge to surgery. However, the use of SEMS for benign colorectal diseases is controversial. The purpose of this retrospective study is to evaluate the efficacy and safety...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X15610052
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16672392
更新日期:2017-01-01 00:00:00
abstract:Background:Postoperative pancreatic collection (POPC) is a frequent complication after pancreatectomy. Although percutaneous drainage (PD) has been the treatment of choice for POPC with encapsulation, endoscopic ultrasound-guided transmural drainage (EUS-TD) was recently reported effective for this condition. The main ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819884418
更新日期:2019-10-24 00:00:00
abstract:Background:The incidence of Clostridioides difficile infection (CDI) is increasing in the general population. Data on the epidemiology of CDI in peripartum women - a highly vulnerable patient population - is scarce. The objective of this study was to report the incidence of CDI in peripartum women. Methods:A single-ce...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820942621
更新日期:2020-07-27 00:00:00
abstract::Severe acute pancreatitis (SAP) is a critical abdominal disease associated with high death rates. A systemic inflammatory response promotes disease progression, resulting in multiple organ dysfunction. The functions of neutrophils in the pathology of SAP have been presumed traditionally to be activation of chemokine a...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820974913
更新日期:2020-11-24 00:00:00
abstract::Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity and mortality. A number of risk factors have been associated with AF, though few studies have explored the association between gastrointestinal and liver diseases and AF. Additionally, AF and treatment for AF ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284819832237
更新日期:2019-04-02 00:00:00
abstract:BACKGROUND:Few reports have described endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) for biliary lesions. In addition, adverse events were not completely examined in previous reports, due to the inclusion of cases in which biliary stents had already been placed. The present study aimed to investigate t...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X15625584
更新日期:2016-05-01 00:00:00
abstract:METHODS:Suboptimal bowel preparation, present in over 20% of colonoscopies, can severely compromise the effectiveness of the colonoscopy procedure. We surveyed 93 primarily urban minority men and women who underwent asymptomatic 'screening' colonoscopy regarding their precolonoscopy bowel-preparation experience. RESUL...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X13498661
更新日期:2013-11-01 00:00:00
abstract:Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820938960
更新日期:2020-07-16 00:00:00
abstract::The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbio...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17694832
更新日期:2017-05-01 00:00:00
abstract::Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with consider...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818759483
更新日期:2018-03-21 00:00:00
abstract:BACKGROUND:Few studies have compared early gastric cancer (EGC) outcomes according to sex and age. METHODS:We retrospectively reviewed 2085 patients who underwent curative gastrectomy for EGC between 1989 and 2000. Prognosis and risk factors for nodal involvement were evaluated according to sex and age. RESULTS:Male ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16681709
更新日期:2017-02-01 00:00:00
abstract::Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated b...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818811294
更新日期:2018-11-25 00:00:00
abstract::Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17722061
更新日期:2017-10-01 00:00:00
abstract:Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820910659
更新日期:2020-03-20 00:00:00
abstract:Background:Recent evidence has shown that the complete blood count (CBC) is abnormal in patients with Crohn's disease (CD). We aimed to investigate an effective CBC parameter and explore its impact on disease activity in a large CD cohort. Methods:We performed a retrospective analysis of patients with established CD w...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820979442
更新日期:2020-12-21 00:00:00
abstract::Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease rangi...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11430859
更新日期:2012-05-01 00:00:00
abstract::Remarkable advancements in techniques of genomic profiling and bioinformatics have led to the accumulation of vast amounts of knowledge on the genomic profiles of biliary tract cancer (BTC). Recent largescale molecular profiling studies have not only highlighted genomic differences characterizing tumors of the intrahe...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17698090
更新日期:2017-06-01 00:00:00
abstract::Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortalit...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X15587481
更新日期:2015-09-01 00:00:00
abstract::The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with n...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346669
更新日期:2010-01-01 00:00:00
abstract::Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremend...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X13508519
更新日期:2014-03-01 00:00:00
abstract::In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11413315
更新日期:2011-11-01 00:00:00
abstract::Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X10369922
更新日期:2010-09-01 00:00:00
abstract::On 31 December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan (Hubei Province of China). In January 2020, a new coronavirus named SARS-CoV2 was isolated and, since that time, SARS-CoV2 related disease (COVID-19) rapidly spread all over the world becoming pan...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820935187
更新日期:2020-06-24 00:00:00
abstract:BACKGROUND:Patients with Barrett's esophagus (BE) are commonly treated with proton-pump inhibitors (PPIs) to minimize the exposure of esophageal mucosa to stomach acid. However, the use of these medications can lead to significant hypergastrinemia in a subset of patients, which is concerning due to the known tumorigeni...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X10392444
更新日期:2011-03-01 00:00:00
abstract::Faecal incontinence, defined as the involuntary loss of solid or liquid stool, is a common problem affecting 0.8-8.3% of the adult population. Individuals suffering from faecal incontinence often live a restricted life with reduced quality of life. The present paper is a clinically oriented review of the pathophysiolo...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X15614516
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Endoscopic therapy for early neoplasia in Barrett's esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA]. ME...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346794
更新日期:2009-11-01 00:00:00